Tyk Medicines Inc. has patented new cyclin-dependent kinase 2 (CDK2) and/or cyclin-dependent kinase 4 (CDK4) inhibitors reported to be useful for the treatment of cancer, infections, metabolic ...

The US Food and Drug Administration (FDA) has granted breakthrough device designation for Acrivon Therapeutics’ ACR-368 ...

Cyclin-dependent kinases (CDKs ... lack at least one of the conserved catalytic residues 2 and may not have kinase activity. Kinase activity has not been detected for several CDK-related proteins ...

New research has identified crucial components and mechanisms of the plant immune system, potentially helping to develop strategies against pathogens.

Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases -WAYNE, Pa., Feb. 12, 2025 ...